515 related articles for article (PubMed ID: 32453377)
1. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.
Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
J Neuromuscul Dis; 2022; 9(4):493-501. PubMed ID: 35634851
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study.
Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
J Neuromuscul Dis; 2023; 10(3):439-447. PubMed ID: 37005891
[TBL] [Abstract][Full Text] [Related]
4. Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study.
Komaki H; Takeshima Y; Matsumura T; Ozasa S; Funato M; Takeshita E; Iwata Y; Yajima H; Egawa Y; Toramoto T; Tajima M; Takeda S
Ann Clin Transl Neurol; 2020 Dec; 7(12):2393-2408. PubMed ID: 33285037
[TBL] [Abstract][Full Text] [Related]
5. Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy.
Czifrus E; Berlau DJ
Expert Rev Neurother; 2023; 23(10):853-858. PubMed ID: 37572081
[TBL] [Abstract][Full Text] [Related]
6. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
Cirak S; Arechavala-Gomeza V; Guglieri M; Feng L; Torelli S; Anthony K; Abbs S; Garralda ME; Bourke J; Wells DJ; Dickson G; Wood MJ; Wilton SD; Straub V; Kole R; Shrewsbury SB; Sewry C; Morgan JE; Bushby K; Muntoni F
Lancet; 2011 Aug; 378(9791):595-605. PubMed ID: 21784508
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
Wagner KR; Kuntz NL; Koenig E; East L; Upadhyay S; Han B; Shieh PB
Muscle Nerve; 2021 Sep; 64(3):285-292. PubMed ID: 34105177
[TBL] [Abstract][Full Text] [Related]
8. Viltolarsen: First Approval.
Dhillon S
Drugs; 2020 Jul; 80(10):1027-1031. PubMed ID: 32519222
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
[TBL] [Abstract][Full Text] [Related]
11. Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy.
Vincik LY; Dautel AD; Staples AA; Lauck LV; Armstrong CJ; Howard JT; McGregor D; Ahmadzadeh S; Shekoohi S; Kaye AD
Adv Ther; 2024 Apr; 41(4):1338-1350. PubMed ID: 38376743
[TBL] [Abstract][Full Text] [Related]
12. Viltolarsen for the treatment of Duchenne muscular dystrophy.
Roshmi RR; Yokota T
Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration of PRO051 in Duchenne's muscular dystrophy.
Goemans NM; Tulinius M; van den Akker JT; Burm BE; Ekhart PF; Heuvelmans N; Holling T; Janson AA; Platenburg GJ; Sipkens JA; Sitsen JM; Aartsma-Rus A; van Ommen GJ; Buyse G; Darin N; Verschuuren JJ; Campion GV; de Kimpe SJ; van Deutekom JC
N Engl J Med; 2011 Apr; 364(16):1513-22. PubMed ID: 21428760
[TBL] [Abstract][Full Text] [Related]
14. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.
Frank DE; Schnell FJ; Akana C; El-Husayni SH; Desjardins CA; Morgan J; Charleston JS; Sardone V; Domingos J; Dickson G; Straub V; Guglieri M; Mercuri E; Servais L; Muntoni F;
Neurology; 2020 May; 94(21):e2270-e2282. PubMed ID: 32139505
[TBL] [Abstract][Full Text] [Related]
15. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
Kinali M; Arechavala-Gomeza V; Feng L; Cirak S; Hunt D; Adkin C; Guglieri M; Ashton E; Abbs S; Nihoyannopoulos P; Garralda ME; Rutherford M; McCulley C; Popplewell L; Graham IR; Dickson G; Wood MJ; Wells DJ; Wilton SD; Kole R; Straub V; Bushby K; Sewry C; Morgan JE; Muntoni F
Lancet Neurol; 2009 Oct; 8(10):918-28. PubMed ID: 19713152
[TBL] [Abstract][Full Text] [Related]
16. Golodirsen for Duchenne muscular dystrophy.
Anwar S; Yokota T
Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.
Voit T; Topaloglu H; Straub V; Muntoni F; Deconinck N; Campion G; De Kimpe SJ; Eagle M; Guglieri M; Hood S; Liefaard L; Lourbakos A; Morgan A; Nakielny J; Quarcoo N; Ricotti V; Rolfe K; Servais L; Wardell C; Wilson R; Wright P; Kraus JE
Lancet Neurol; 2014 Oct; 13(10):987-96. PubMed ID: 25209738
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.
Mendell JR; Sahenk Z; Lehman K; Nease C; Lowes LP; Miller NF; Iammarino MA; Alfano LN; Nicholl A; Al-Zaidy S; Lewis S; Church K; Shell R; Cripe LH; Potter RA; Griffin DA; Pozsgai E; Dugar A; Hogan M; Rodino-Klapac LR
JAMA Neurol; 2020 Sep; 77(9):1122-1131. PubMed ID: 32539076
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy.
López-Martínez A; Soblechero-Martín P; Arechavala-Gomeza V
Methods Mol Biol; 2022; 2434():217-233. PubMed ID: 35213020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
